KPTI Karyopharm Therapeutics Inc

Price (delayed)

$0.9322

Market cap

$109.73M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.27

Enterprise value

$254.77M

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related ...

Highlights
The EPS has grown by 29% YoY
The net income has grown by 7% YoY but it has contracted by 2.3% from the previous quarter
Karyopharm Therapeutics's quick ratio has decreased by 43% YoY and by 13% from the previous quarter
The equity has contracted by 24% from the previous quarter

Key stats

What are the main financial stats of KPTI
Market
Shares outstanding
117.71M
Market cap
$109.73M
Enterprise value
$254.77M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.81
Earnings
Revenue
$140.46M
EBIT
-$122.05M
EBITDA
-$121.72M
Free cash flow
-$117.73M
Per share
EPS
-$1.27
Free cash flow per share
-$1.02
Book value per share
-$1.47
Revenue per share
$1.22
TBVPS
$1.77
Balance sheet
Total assets
$204.46M
Total liabilities
$373.41M
Debt
$176.44M
Equity
-$168.96M
Working capital
$133.03M
Liquidity
Debt to equity
-1.04
Current ratio
3.04
Quick ratio
2.76
Net debt/EBITDA
-1.19
Margins
EBITDA margin
-86.7%
Gross margin
96.1%
Net margin
-104.2%
Operating margin
-94.3%
Efficiency
Return on assets
-57.8%
Return on equity
N/A
Return on invested capital
-38.9%
Return on capital employed
-87.7%
Return on sales
-86.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KPTI stock price

How has the Karyopharm Therapeutics stock price performed over time
Intraday
2.44%
1 week
-6.78%
1 month
-4.88%
1 year
-43.84%
YTD
7.77%
QTD
7.15%

Financial performance

How have Karyopharm Therapeutics's revenue and profit performed over time
Revenue
$140.46M
Gross profit
$134.96M
Operating income
-$132.4M
Net income
-$146.34M
Gross margin
96.1%
Net margin
-104.2%
The net income has grown by 7% YoY but it has contracted by 2.3% from the previous quarter
KPTI's net margin is down by 6% from the previous quarter but it is up by 2.3% YoY
The company's gross profit fell by 6% YoY and by 4.3% QoQ
KPTI's operating margin is down by 6% QoQ

Growth

What is Karyopharm Therapeutics's growth rate over time

Valuation

What is Karyopharm Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.81
The EPS has grown by 29% YoY
The equity has contracted by 24% from the previous quarter
The P/S is 91% lower than the 5-year quarterly average of 8.0 and 32% lower than the last 4 quarters average of 1.1
The revenue has contracted by 5% YoY and by 3.8% from the previous quarter

Efficiency

How efficient is Karyopharm Therapeutics business performance
KPTI's ROA is down by 14% QoQ and by 7% YoY
Karyopharm Therapeutics's return on invested capital has decreased by 9% QoQ but it has increased by 8% YoY
The ROS has contracted by 7% from the previous quarter but it has grown by 3.7% YoY

Dividends

What is KPTI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KPTI.

Financial health

How did Karyopharm Therapeutics financials performed over time
KPTI's total assets is 45% smaller than its total liabilities
Karyopharm Therapeutics's quick ratio has decreased by 43% YoY and by 13% from the previous quarter
The current ratio has contracted by 41% YoY and by 10% from the previous quarter
KPTI's debt to equity has surged by 74% year-on-year and by 20% since the previous quarter
The equity has contracted by 24% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.